ASCO 2025

De-escalating therapy - a step forward

Practice changing results for EBC patients?

HRD and BRCA status as a new innovative staging system?

Risk according to NATALEE / MonarchE in WSG-ADAPT trial

WSG: HER2+ pooled analysis

Intraoperative dose escalation helps to reach targeted dose of abemaciclib

TRADE: Abemaciclib in eBC

ctDNA for the early detection of molecular recurrence

Next-gen endocrine therapies and ADCs: Updates from EMBER-3 and DB-06

SG + Pembro in aTNBC: a new standard of care?

AI and ADCs: Precision diagnostics & safer rechallenge in HER2+ breast cancer

A new standard for endocrine-resistant HR+ MBC?

New compounds - new approaches: TNBC | HR+ | HER2+

Triple therapy 1st line | double therapy 2nd line - new treatment options for HR+ breast cancer patients

A new standard for the firstline treatment of HER2+ patients?

A new first-line therapy for TNBC

Liquid biopsy as a navigator for personalized therapy guidance

ABC for metastatic TNBC

New firstline SOC for HER2+ metastatic BC

Vepdegestrant for treatment of ER+/HER2- aBC

Ipataserib + Fulvestrant improves PFS in PIK3CA-altered pathway in patients with HER2-/ER+ BC

New SOC in first-line treatment for primary endocrine resistance

T-DXd: Detecting ILD and treat again

Future new SOC for PD-L1-positive mTNBC

Effective ADC for HER2+ mBC with brain metastases

Final OS-Analysis of INAVO-120 trial

Additional chemo-free option for TNBC

ASCENT-04

SG + Pembrolizumab might become SOC for PD-L1-positive advanced TNBC

Additional ADC effective for untreated TNBC

New treatment option in first line of metastatic TNBC

New AKT/PIK3 Antagonist for treatment of mBC after CDK4/6 inhibitor treatment

Re-exposition and ILD

Sac-TMT for metastatic TNBC

OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.

Nuova opzione di trattamento in prima linea per il TNBC metastatico

Una nuova terapia di prima linea per il TNBC

Ipatasertib + Fulvestrant mejora la supervivencia libre de progresión en la vía alterada de PIK3CA en pacientes con cáncer de mama HER2 negativo y receptores de estrógeno positivos.

Nuovo antagonista di AKT/PIK3 per il trattamento della mBC dopo il trattamento con inibitori CDK4/6

Vepdegestrant per il trattamento di ER+/HER2- aBC

Un nouveau traitement de première ligne pour le TNBC

SG + Pembrolizumab podría convertirse en el tratamiento estándar para el TNBC avanzado con PD-L1 positivo.

Analisi finale della OS dello studio INAVO-120

A bright future? Radioligands, hormonal treatment options and bispecific T-cell engagers

The role of ARPIs in mHSPCThe role of ARPIs in mHSPC

PARP-inhibitor combinations in advanced prostate cancer

Stereotactic beam radiation therapy 2.0

New way of treatment for PCa

Rebirth of Rucaparib

Localized CSPC - innovations

Real world data from ironman registry confirms prognostic values for PSA

Adding EZH2 to Enzalutamide to decrease the development of antiandrogen resistance

MMAI Model identifies patients who benfit from ARPI in STAMPEDE

mHSPC - ADT + NHT updates

Combination of LU-PSMA and immunotherapy, EVOLUTION trial

Immuntherapy - an evolution?

mHSPC - prognostification - indications on integration?

News of ANZUP trial

Artera MMAI score en prediktiv biomarkör i STAMPEDE M0 studien

Real-world data från Ironman: PSA nivå en viktig prognostisk markör

Evolution: Kombination av LuPSMA och immunterapi.

Sasanlimab + BCG: Practice-Changing Potential for Aggressive NMIBC

ctDNA Clearance Confirms Added Value of Perioperative Durvalumab in MIBC

Complete but Not Finished: EV+P cCR Data Extend the SOC Case

ICI Combos in 1L and Maintenance – Mixed Bags or Meaningful Moves?

Update on EV-PEM in the EV-302 study

mUC EVP + subsequent therapies

New option for high-risk NMIBC

UTUC - enlighted

mUC - new approaches?

Intensive caution of BCG Therapy

A new prognostic factor in bladder cancer?: The case of ctDNA

CREST Study: Promising Results with PD-1 Inhibitor Sasanlimab in High-Risk BCG-Unresponsive NMIBC

Response matters in advanced urothelial cancer patients treated with EV-Pembro

ASCO 2025 - Highlights for Bladder Cancer

New nectin-4 ADCs are coming

The role of sansalimab (+ SG) in BCG-naive and BCG-refractory MIBC

Benefit of IO/IO therapy in mUC

NIAGARA study and circulating tumor DNA

ASCO 2025 - Στιγμιότυπα για τον καρκίνο της ουροδόχου κύστης

HIF alfa sigue siendo una diana interesante en el RCC y otras enfermedades causadas por VHL

La respuesta es importante en pacientes con cáncer urotelial avanzado tratados con EV-Pembro

El rol de sansalimab (+ SG) en el carcinoma urotelial muscularmente invasivo en pacientes naïve y refractarios al tratamiento con BCG.

De nouveaux ADC pour la nectine-4 arrivent

¿Un nuevo factor pronóstico en el cáncer de vejiga? El caso del ctDNA

Who Really Benefits? Pembro’s Solid, Atezo’s Still Digging for Answers

9 Years of CheckMate 214 – Is Nivo + Ipi Still Holding Up?

PDIGREE: Real-Life Answers for Post-Ipi/Nivo Decisions

Casdatifan + Cabo – Too Early to Call It a Game Changer?

First lession

Long-term outcome of Nnivo-Ipi in clear cell RCC

Zanzalitinib + Nivolumab +/- Relatlimab in Front-line mRCC

Allogeneic CD70 CAR T Cells in refractory RCC

HIF alpha still an interesting target in RCC and other VHL driven diseases

5-Year OS data from the KEYNOTE-564 study

Nivo + Ipi - Update & Insights

New synergies? Radiotherapy and IO in Limited-Stage SCLC and Unresectable Stage III NSCLC

Neoadjuvant Approaches in resectable NSCLC: Insights from CheckMate 816 and NeoADAURA

Chemoimmunotherapy followed by chemoradiotherapy

Updates in perioperative strategies in NSCLC

cTDNA in periop chemo-IO strategies

Neadjuvant targeted therapy

CM-816: The OS results are positive and demonstrate that chemo-IO should be administered prior to surgery

MRD-analysis of the AEGEAN-trial

Neoadjuvant Alectinib in resectable stage III NSCLC

ctDNA stratification

CheckMate 816: Update on OS-benefit

CM-816 : Les résultats de l'OS sont positifs et démontrent que la chemo-IO doit être administrée avant l'intervention chirurgicale

CheckMate 816 : Mise à jour sur les avantages du système d'exploitation

Actualizaciones en estrategias perioperatorias en NSCLC

New options in First-Line Therapy in metastatic NSCLC

Targeting rare mutations in metastatic NSCLC - HER2 and EGFR Exon 20

What is the future in the field of EGFR resistance?

HERTHENA-Lung02 unfortunately negative study - withdrawal of licence application

Time of day of immunotherapy is important

RELA-104-biomarker-analysis

ADC in the 3L beats docetaxel

Does the timing of IO-infusion impact survival?

Sevarbertinib – an additional option for HER2 exon 20 alterations

KRAS G12C: Can immunotherapy improve patient outcome alone?

Is there still a place for HER3-DXd in advanced NSCLC?

Updates on ADCs in EGFR resistance

TROP2 targets – where is first-line development heading?

ADC as 3L in EGFR

GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved outcome?

HER3-DXd: dissapointing negative trial

Immunotherapy – before or after 3 p.m.?

Benefit of IO is depending on the time of day of administration

Have we MET our target?

HERTHENA-Lung02 étude malheureusement négative - retrait de la demande d'autorisation

Hebben we ons doel gehaald?

Is er nog een plaats voor HER3-DXd in gevorderd NSCLC?

Actualizaciones sobre los ADC en la resistencia al EGFR

KRAS G12C: Kan immunotherapie alleen het resultaat voor de patiënt verbeteren?

Redefining SCLC: Lubri/Atezo maintenance in 1L, Tarlatamab as new SOC in 2L, and a new trispecific T-cell Engager

New therapies to improve patient survival

New maintenance therapy for SCLC

Tarlatamab - a new SOC in second line

Taralatamb - the new SOC in 2L treatment

The first positive maintenance therapy in SCLC

DeLLphi-304: Dramatic change in 2L-treatment in SCLC

De nouvelles thérapies pour améliorer la survie des patients

DeLLphi-304 : Changement radical dans le traitement de deuxième ligne du cancer du SCLC

LA HNSCC - New neoadjuvant SOC

Exercise - The new old wonderdrug